Centrexion Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
200 State St Ste 6, Boston, Massachusett...Phone Number
(617) 837-6911Website
www.centrexion.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
1
1
1
About Centrexion Therapeutics
Centrexion Therapeutics is a dynamic company focused on addressing unmet needs in the fields of non-opioid pain relief and immunology. Led by an experienced team, the company is strategically building a portfolio aimed at transforming the treatment of pain and autoimmune diseases. They collaborate with prestigious partners such as Lilly and Boehringer Ingelheim to target high-value markets with significant unmet needs. With growing support for non-opioid drug development, Centrexion is poised to make meaningful advancements in these emerging categories.Explore more
Centrexion Therapeutics Org Chart
CO
Chief Medical Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Centrexion Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Centrexion Therapeutics launches new products
Centrexion Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Centrexion Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Centrexion Therapeutics recently announced quarterly report
Click to see if Centrexion Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Centrexion Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Centrexion Therapeutics
Check out if Centrexion Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Centrexion Therapeutics
Compare insights from companies similar to Centrexion Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Centrexion Therapeutics
<$5M
11-50
Private
$181.8M
2013
JC
James CampbellPresident & Chief Scientific Officer
Company Profile Activity
Activity Insights
Centrexion Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Centrexion Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Centrexion Therapeutics.
Centrexion Therapeutics financials insights
Gather financial insights about Centrexion Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series A
$8.8M
Series B
$14.7M
2016
Multiple Rounds
$45.6M
2017
Angel/Seed
$5.3M
2018
Series D
$67M
2020
Other Financing Round
$40.5M
Centrexion Therapeutics Tech Stack
A closer look at the technologies used by Centrexion Therapeutics
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Centrexion Therapeutics News & Media
ARTIS Ventures Welcomes Jeff Kindler as Operating Partner
Centrexion Therapeutics CEO, Former Pfizer CEO, Brings Decades of Business Experience to Firm Centrexion Therapeutics CEO, Former Pfizer CEO, Brings Decades of Business Experience to FirmLilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the ...Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference and Osteoarthritis Research Society International 2019 World Congress
BOSTON, April 29, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced it will present one poster on CNTX-4975 at the 2019 British Society for Rheumatology (BSR) Annual Conference taking place April 30-May 2, 2019 in Birmingham, UK and four posters on CNTX-4975 at the Osteoarthritis Research Society International (OARSI) 2019 World Congress taking place May 2-5, 2019
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Centrexion Therapeutics
Sign Up For FreeTo access detailed company insights
Centrexion Therapeutics is a dynamic company focused on addressing unmet needs in the fields of non-opioid pain relief and immunology. Led by an experienced team, the company is strategically building a portfolio aimed at transforming the treatment of pain and autoimmune diseases. They collaborate with prestigious partners such as Lilly and Boehrin... Read More
